These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 11310375)

  • 41. p53 and c-jun expression in urinary bladder transitional cell carcinoma: correlation with proliferating cell nuclear antigen (PCNA) histological grade and clinical stage.
    Skopelitou A; Hadjiyannakis M; Dimopoulos D; Kamina S; Krikoni O; Alexopoulou V; Rigas C; Agnantis NJ
    Eur Urol; 1997; 31(4):464-71. PubMed ID: 9187909
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The relation between p53 overexpression and lymph node metastases in clinical stage t2 and t3a transitional cell bladder carcinoma.
    Uygur MC; Yaman I; Kutluay L; Altuğ U; Erol D
    J Exp Clin Cancer Res; 1999 Sep; 18(3):391-5. PubMed ID: 10606186
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Overexpression of Bcl-2 in bladder cancer cells inhibits apoptosis induced by cisplatin and adenoviral-mediated p53 gene transfer.
    Miyake H; Hanada N; Nakamura H; Kagawa S; Fujiwara T; Hara I; Eto H; Gohji K; Arakawa S; Kamidono S; Saya H
    Oncogene; 1998 Feb; 16(7):933-43. PubMed ID: 9484785
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relationship of p53 and bcl-2 to prognosis in muscle-invasive transitional cell carcinoma of the bladder.
    Glick SH; Howell LP; White RW
    J Urol; 1996 May; 155(5):1754-7. PubMed ID: 8627878
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nested variant of urothelial carcinoma: a clinicopathologic and immunohistochemical study of 12 cases.
    Lin O; Cardillo M; Dalbagni G; Linkov I; Hutchinson B; Reuter VE
    Mod Pathol; 2003 Dec; 16(12):1289-98. PubMed ID: 14681330
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Clinical significance of p53, MDM2 and bcl-2 expression in transitional cell carcinoma of the bladder.
    Uchida T; Minei S; Gao JP; Wang C; Satoh T; Baba S
    Oncol Rep; 2002; 9(2):253-9. PubMed ID: 11836589
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Proliferative activity is the most significant predictor of recurrence in noninvasive papillary urothelial neoplasms of low malignant potential and grade 1 papillary carcinomas of the bladder.
    Pich A; Chiusa L; Formiconi A; Galliano D; Bortolin P; Comino A; Navone R
    Cancer; 2002 Aug; 95(4):784-90. PubMed ID: 12209722
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Fluorescence in situ hybridization identifies more aggressive types of primarily noninvasive (stage pTa) bladder cancer.
    Pycha A; Mian C; Haitel A; Hofbauer J; Wiener H; Marberger M
    J Urol; 1997 Jun; 157(6):2116-9. PubMed ID: 9146595
    [TBL] [Abstract][Full Text] [Related]  

  • 49. p53 status does not predict initial clinical response to bacillus Calmette-Guerin intravesical therapy in T1 bladder tumors.
    Pages F; Flam TA; Vieillefond A; Molinie V; Abeille X; Lazar V; Bressac-de Paillerets B; Mosseri V; Zerbib M; Fridman WH; Debré B; Thiounn N
    J Urol; 1998 Mar; 159(3):1079-84. PubMed ID: 9474235
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The relation of mutant p53 accumulation in transitional cell carcinoma of bladder with pathological stage, grade, recurrence and survival.
    Yeniyol CO; Süelözgen T; Vardar E; Sural S; Postaci H; Ayder AR
    Int Urol Nephrol; 2001; 33(3):473-8. PubMed ID: 12230275
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immunohistochemical analysis of bcl-2 expression in transitional cell carcinoma of the bladder.
    Shiina H; Igawa M; Urakami S; Honda S; Shirakawa H; Ishibe T
    J Clin Pathol; 1996 May; 49(5):395-9. PubMed ID: 8707954
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunohistochemical detection of p53 protein overexpression versus gene sequencing in urinary bladder carcinomas.
    Bernardini S; Adessi GL; Billerey C; Chezy E; Carbillet JP; Bittard H
    J Urol; 1999 Oct; 162(4):1496-501. PubMed ID: 10492244
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Expression of c-erb-B2 gene in bladder cancer of Egyptian patients and its correlation with p53 and bcl-2.
    Sakr SA; Mahran HA; Fahmy AM; El-Kholy MA; Meawad M
    Biomed Pharmacother; 2015 Dec; 76():73-81. PubMed ID: 26653553
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Comparative study of P 53, Bcl-2, and C-erbB-2 expression in low-grade papillary bladder tumors].
    Ramos Soler D; Navarro Fos S; Villamón Fort R; Gil Salom M; Llombart Bosch A
    Arch Esp Urol; 2003 Apr; 56(3):277-85. PubMed ID: 12768988
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Decreased Fas expression in advanced-stage bladder cancer is not related to p53 status.
    Maas S; Warskulat U; Steinhoff C; Mueller W; Grimm MO; Schulz WA; Seifert HH
    Urology; 2004 Feb; 63(2):392-7. PubMed ID: 14972509
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Altered mRNA expression of the Rb and p16 tumor suppressor genes and of CDK4 in transitional cell carcinomas of the urinary bladder associated with tumor progression.
    Quentin T; Henke C; Korabiowska M; Schlott T; Zimmerman B; Kunze E
    Anticancer Res; 2004; 24(2B):1011-23. PubMed ID: 15161057
    [TBL] [Abstract][Full Text] [Related]  

  • 57. p53 mutations in bladder tumors inactivate the transactivation of the p21 and Bax genes, and have a predictive value for the clinical outcome after bacillus Calmette-Guerin therapy.
    Pfister C; Flaman JM; Dunet F; Grise P; Frebourg T
    J Urol; 1999 Jul; 162(1):69-73. PubMed ID: 10379742
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [The molecular biology of bladder carcinoma].
    Moreno Sierra J; Maestro de las Casas ML; Chicharro Almarza J; Ortega Heredia MD; López García-Asenjo J; Merino Sánchez C; Blanco Jiménez E; Silmi Moyano A; Rsesel Estévez L
    Arch Esp Urol; 1997 Oct; 50(8):855-66. PubMed ID: 9463283
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Expression of Maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis.
    Friedrich MG; Toma MI; Petri S; Cheng JC; Hammerer P; Erbersdobler A; Huland H
    Eur Urol; 2004 Jun; 45(6):737-43. PubMed ID: 15149745
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Predictive value of cell cycle biomarkers in nonmuscle invasive bladder transitional cell carcinoma.
    Shariat SF; Ashfaq R; Sagalowsky AI; Lotan Y
    J Urol; 2007 Feb; 177(2):481-7; discussion 487. PubMed ID: 17222615
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.